{"id":25210,"date":"2025-05-07T12:22:17","date_gmt":"2025-05-07T12:22:17","guid":{"rendered":"https:\/\/www.euforea.org\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/"},"modified":"2026-08-20T07:57:06","modified_gmt":"2026-08-20T07:57:06","slug":"ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/","title":{"rendered":"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos?"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"25210\" class=\"elementor elementor-25210 elementor-14437\" data-elementor-post-type=\"news\">\n\t\t\t\t<div class=\"elementor-element elementor-element-758e8f9 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no e-con e-parent\" data-id=\"758e8f9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1a3d38b elementor-widget elementor-widget-euforea_general_content\" data-id=\"1a3d38b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"euforea_general_content.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"paragraphs\">\n    <div data-quickedit-entity-id=\"paragraph\/842\" class=\"paragraph paragraph--text-columns paragraph-id--842 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n      <div class=\"inner--wide\">\n        <div class=\"text__text text text--paragraph\">\n        \t          <p>La rinitis al\u00e9rgica es una enfermedad de alta prevalencia, un trastorno inflamatorio de la mucosa nasal causado por una reacci\u00f3n a diversos al\u00e9rgenos. Adem\u00e1s, es un factor de riesgo para varias comorbilidades, incluyendo asma al\u00e9rgica y rinosinusitis cr\u00f3nica con p\u00f3lipos nasales; todas estas afecciones comparten una patolog\u00eda com\u00fan basada en la inflamaci\u00f3n tipo 2. <\/p>\n<p>El pilar fundamental del tratamiento sigue siendo los glucocorticosteroides intranasales y los antihistam\u00ednicos, con la adici\u00f3n breve de corticosteroides orales para los pacientes m\u00e1s gravemente afectados. Pero para los pacientes con rinitis al\u00e9rgica grave, la inmunoterapia al\u00e9rgeno-espec\u00edfica, tambi\u00e9n llamada AIT, que existe desde hace m\u00e1s de 100 a\u00f1os, es una opci\u00f3n terap\u00e9utica. Puede conducir al alivio de los s\u00edntomas, la prevenci\u00f3n de la progresi\u00f3n de la enfermedad e incluso la curaci\u00f3n.  <\/p>\n<p>Muchos biol\u00f3gicos son muy caros, pero dada la reciente reducci\u00f3n de los costes del omalizumab y la disponibilidad de f\u00e1rmacos menos costosos con actividades similares, llamados biosimilares, esta opci\u00f3n se ha vuelto cada vez m\u00e1s viable para quienes tratan a pacientes con rinitis al\u00e9rgica grave.<\/p>\n<p>En este debate, analizaremos nuestra posici\u00f3n respecto a la inmunoterapia al\u00e9rgeno-espec\u00edfica (AIT) y los biol\u00f3gicos en pacientes con rinitis al\u00e9rgica grave.<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a90452 elementor-widget elementor-widget-video\" data-id=\"2a90452\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/youtu.be\\\/OAPbZPOF6Ag&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3a05105 elementor-widget elementor-widget-Team\" data-id=\"3a05105\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Team.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"paragraphs\">\n\t\t\t<div data-quickedit-entity-id=\"paragraph\/876\" class=\"paragraph paragraph--text-columns paragraph-id--876 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t  <div class=\"inner--wide\">\n\t\t    <div class=\"text__text text text--paragraph\">\n\t\t      <h2>Ponentes<\/h2>\n\t\t    <\/div>\n\t\t  <\/div>\n\t\t<\/div>\n\t\t\t\t<div data-quickedit-entity-id=\"paragraph\/98\" class=\"paragraph paragraph-id--98 paragraph--type--team paragraph--view-mode--default team clearfix\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t  <div class=\"inner--wide\">\n\t\t  \t\t\t    <div class=\"team__container\">\n\t\t    \t\t\t\t      <a data-quickedit-entity-id=\"paragraph\/97\" class=\"paragraph paragraph-id--97 paragraph--type--team-member paragraph--view-mode--default team__member clearfix\" href=\"\" style=\"background-image:url(https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/michael-blaiss.jpeg?h=70c48a26&amp;itok=tDy3Wfhq)\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t\t      \t\t\t\t        <div class=\"team__member__overlay\">\n\t\t\t        \t\t\t          \t<div class=\"team__member__name\"> Prof. Michael Blaiss <\/div>\n\t\t\t        \t\t\t        \t\t\t          \t\t\t        <\/div>\n\t\t\t      <\/a>\n\t\t\t  \t\t\t      <a data-quickedit-entity-id=\"paragraph\/97\" class=\"paragraph paragraph-id--97 paragraph--type--team-member paragraph--view-mode--default team__member clearfix\" href=\"\" style=\"background-image:url(https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Pete-Smith.jpg?h=70c48a26&amp;itok=tDy3Wfhq)\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t\t      \t\t\t\t        <div class=\"team__member__overlay\">\n\t\t\t        \t\t\t          \t<div class=\"team__member__name\"> Prof. Pete Smith <\/div>\n\t\t\t        \t\t\t        \t\t\t          \t\t\t        <\/div>\n\t\t\t      <\/a>\n\t\t\t  \t\t\t      <a data-quickedit-entity-id=\"paragraph\/97\" class=\"paragraph paragraph-id--97 paragraph--type--team-member paragraph--view-mode--default team__member clearfix\" href=\"\" style=\"background-image:url(https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Enrico-Heffler0-1.jpeg?h=70c48a26&amp;itok=tDy3Wfhq)\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t\t      \t\t\t\t        <div class=\"team__member__overlay\">\n\t\t\t        \t\t\t          \t<div class=\"team__member__name\"> Prof. Enrico Heffler <\/div>\n\t\t\t        \t\t\t        \t\t\t          \t\t\t        <\/div>\n\t\t\t      <\/a>\n\t\t\t  \t\t\t      <a data-quickedit-entity-id=\"paragraph\/97\" class=\"paragraph paragraph-id--97 paragraph--type--team-member paragraph--view-mode--default team__member clearfix\" href=\"\" style=\"background-image:url(https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Ulrich-Wahn_0.png?h=70c48a26&amp;itok=tDy3Wfhq)\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n\t\t\t      \t\t\t\t        <div class=\"team__member__overlay\">\n\t\t\t        \t\t\t          \t<div class=\"team__member__name\"> Prof. Ulrich Wahn <\/div>\n\t\t\t        \t\t\t        \t\t\t          \t\t\t        <\/div>\n\t\t\t      <\/a>\n\t\t\t  \t\t    <\/div>\n\t\t  <\/div>\n\t\t<\/div>\n\t<\/div>\n<style type=\"text\/css\">.elementor .elementor-widget-Team  *, .elementor .elementor-widget-Team :after,.elementor .elementor-widget-Team :before{\n\tbox-sizing: initial;\n}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>La rinitis al\u00e9rgica es una enfermedad de alta prevalencia, un trastorno inflamatorio de la mucosa nasal causado por una reacci\u00f3n a diversos al\u00e9rgenos. Adem\u00e1s, es un factor de riesgo para varias comorbilidades, incluyendo asma al\u00e9rgica y rinosinusitis cr\u00f3nica con p\u00f3lipos nasales; todas estas afecciones comparten una patolog\u00eda com\u00fan basada en la inflamaci\u00f3n tipo 2. El pilar fundamental del tratamiento sigue siendo los glucocorticosteroides intranasales y los antihistam\u00ednicos, con la adici\u00f3n breve de corticosteroides orales para los pacientes m\u00e1s gravemente afectados. Pero para los pacientes con rinitis al\u00e9rgica grave, la inmunoterapia al\u00e9rgeno-espec\u00edfica, tambi\u00e9n llamada AIT, que existe desde hace m\u00e1s de 100 a\u00f1os, es una opci\u00f3n terap\u00e9utica. Puede conducir al alivio de los s\u00edntomas, la prevenci\u00f3n de la progresi\u00f3n de la enfermedad e incluso la curaci\u00f3n. Muchos biol\u00f3gicos son muy caros, pero dada la reciente reducci\u00f3n de los costes del omalizumab y la disponibilidad de f\u00e1rmacos menos costosos con actividades similares, llamados biosimilares, esta opci\u00f3n se ha vuelto cada vez m\u00e1s viable para quienes tratan a pacientes con rinitis al\u00e9rgica grave. En este debate, analizaremos nuestra posici\u00f3n respecto a la inmunoterapia al\u00e9rgeno-espec\u00edfica (AIT) y los biol\u00f3gicos en pacientes con rinitis al\u00e9rgica grave. Ponentes Prof. Michael Blaiss Prof. Pete Smith Prof. Enrico Heffler Prof. Ulrich Wahn<\/p>\n","protected":false},"author":9,"featured_media":25214,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-25210","news","type-news","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos? - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos?\" \/>\n<meta property=\"og:description\" content=\"La rinitis al\u00e9rgica es una enfermedad de alta prevalencia, un trastorno inflamatorio de la mucosa nasal causado por una reacci\u00f3n a diversos al\u00e9rgenos. Adem\u00e1s, es un factor de riesgo para varias comorbilidades, incluyendo asma al\u00e9rgica y rinosinusitis cr\u00f3nica con p\u00f3lipos nasales; todas estas afecciones comparten una patolog\u00eda com\u00fan basada en la inflamaci\u00f3n tipo 2. El pilar fundamental del tratamiento sigue siendo los glucocorticosteroides intranasales y los antihistam\u00ednicos, con la adici\u00f3n breve de corticosteroides orales para los pacientes m\u00e1s gravemente afectados. Pero para los pacientes con rinitis al\u00e9rgica grave, la inmunoterapia al\u00e9rgeno-espec\u00edfica, tambi\u00e9n llamada AIT, que existe desde hace m\u00e1s de 100 a\u00f1os, es una opci\u00f3n terap\u00e9utica. Puede conducir al alivio de los s\u00edntomas, la prevenci\u00f3n de la progresi\u00f3n de la enfermedad e incluso la curaci\u00f3n. Muchos biol\u00f3gicos son muy caros, pero dada la reciente reducci\u00f3n de los costes del omalizumab y la disponibilidad de f\u00e1rmacos menos costosos con actividades similares, llamados biosimilares, esta opci\u00f3n se ha vuelto cada vez m\u00e1s viable para quienes tratan a pacientes con rinitis al\u00e9rgica grave. En este debate, analizaremos nuestra posici\u00f3n respecto a la inmunoterapia al\u00e9rgeno-espec\u00edfica (AIT) y los biol\u00f3gicos en pacientes con rinitis al\u00e9rgica grave. Ponentes Prof. Michael Blaiss Prof. Pete Smith Prof. Enrico Heffler Prof. Ulrich Wahn\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T07:57:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1748\" \/>\n\t<meta property=\"og:image:height\" content=\"1015\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/\",\"name\":\"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos? - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg\",\"datePublished\":\"2025-05-07T12:22:17+00:00\",\"dateModified\":\"2026-08-20T07:57:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/elige-tu-camino\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos? - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/","og_locale":"es_ES","og_type":"article","og_title":"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos?","og_description":"La rinitis al\u00e9rgica es una enfermedad de alta prevalencia, un trastorno inflamatorio de la mucosa nasal causado por una reacci\u00f3n a diversos al\u00e9rgenos. Adem\u00e1s, es un factor de riesgo para varias comorbilidades, incluyendo asma al\u00e9rgica y rinosinusitis cr\u00f3nica con p\u00f3lipos nasales; todas estas afecciones comparten una patolog\u00eda com\u00fan basada en la inflamaci\u00f3n tipo 2. El pilar fundamental del tratamiento sigue siendo los glucocorticosteroides intranasales y los antihistam\u00ednicos, con la adici\u00f3n breve de corticosteroides orales para los pacientes m\u00e1s gravemente afectados. Pero para los pacientes con rinitis al\u00e9rgica grave, la inmunoterapia al\u00e9rgeno-espec\u00edfica, tambi\u00e9n llamada AIT, que existe desde hace m\u00e1s de 100 a\u00f1os, es una opci\u00f3n terap\u00e9utica. Puede conducir al alivio de los s\u00edntomas, la prevenci\u00f3n de la progresi\u00f3n de la enfermedad e incluso la curaci\u00f3n. Muchos biol\u00f3gicos son muy caros, pero dada la reciente reducci\u00f3n de los costes del omalizumab y la disponibilidad de f\u00e1rmacos menos costosos con actividades similares, llamados biosimilares, esta opci\u00f3n se ha vuelto cada vez m\u00e1s viable para quienes tratan a pacientes con rinitis al\u00e9rgica grave. En este debate, analizaremos nuestra posici\u00f3n respecto a la inmunoterapia al\u00e9rgeno-espec\u00edfica (AIT) y los biol\u00f3gicos en pacientes con rinitis al\u00e9rgica grave. Ponentes Prof. Michael Blaiss Prof. Pete Smith Prof. Enrico Heffler Prof. Ulrich Wahn","og_url":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","article_modified_time":"2026-08-20T07:57:06+00:00","og_image":[{"width":1748,"height":1015,"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/","url":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/","name":"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos? - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg","datePublished":"2025-05-07T12:22:17+00:00","dateModified":"2026-08-20T07:57:06+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Innovation-Forum-on-Severe-Allergic-Rhinitis-Teaser-Watch-Now.jpg","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/es\/news\/ait-y-biologicos-en-rinitis-alergica-grave-donde-nos-encontramos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.euforea.org\/es\/elige-tu-camino\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"AIT y Biol\u00f3gicos en Rinitis Al\u00e9rgica Grave: \u00bfD\u00f3nde nos encontramos?"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/25210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/comments?post=25210"}],"version-history":[{"count":1,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/25210\/revisions"}],"predecessor-version":[{"id":25215,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/25210\/revisions\/25215"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media\/25214"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media?parent=25210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/categories?post=25210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/tags?post=25210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}